[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 26 of about 26
1. Karavasilis V, Seddon BM, Ashley S, Al-Muderis O, Fisher C, Judson I: Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients. Cancer; 2008 Apr 1;112(7):1585-91
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients.
  • BACKGROUND: The efficacy of palliative chemotherapy was investigated in a large group of patients with advanced soft-tissue sarcomas (STS) treated on routine palliative protocols.
  • METHODS: Patients with STS who had first-line chemotherapy for advanced and/or metastatic disease between 1991 and 2005 were identified from the Royal Marsden Hospital's sarcoma database.
  • Patients with Ewing sarcoma, rhabdomyosarcoma, desmoplastic small round cell tumor, and gastrointestinal stromal tumors were excluded from the study.
  • The median age was 49 years and the majority (83%) received chemotherapy for metastatic disease.
  • The most common histologic subtypes were leiomyosarcoma (35%) synovial sarcoma (13%), liposarcoma (10%), and malignant fibrous histiocytoma (10%).
  • In all, 61% received single-agent chemotherapy, usually doxorubicin.
  • An objective response was reported in 33% of patients (53% in those with synovial sarcoma); 22% had stable disease and 45% derived 'clinical benefit' (objective responses + stable disease for >or= 6 months).
  • In multivariate analysis, age <40 years, liposarcoma, and synovial histology were found to be positive, and bone involvement to be negative, independent prognostic factors.
  • Patients treated with combination chemotherapy experienced longer OS than those treated with a single agent.
  • CONCLUSIONS: Palliative chemotherapy may be beneficial in approximately half of patients with advanced STS.
  • Synovial sarcoma and liposarcoma subtypes have a better prognosis.
  • [MeSH-major] Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Male. Middle Aged. Neoplasm Staging. Palliative Care. Prognosis. Prospective Studies. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18278813.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


2. Bisogno G, Sotti G, Nowicki Y, Ferrari A, Garaventa A, Zanetti I, Favre C, Schiavetti A, Tamaro P, Carli M: Soft tissue sarcoma as a second malignant neoplasm in the pediatric age group. Cancer; 2004 Apr 15;100(8):1758-65
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soft tissue sarcoma as a second malignant neoplasm in the pediatric age group.
  • BACKGROUND: Survivors of childhood malignancies have an increased risk of developing second malignant neoplasms (SMN) due to their prior treatment and/or genetic susceptibility.
  • A small proportion of SMNs are soft tissue sarcomas (STS), whose prognosis is generally thought to be poor, though publications on such patients' treatment and outcome is limited.
  • The primary tumor was STS in five patients; Hodgkin disease in five patients; leukemia in four patients; retinoblastoma, neuroblastoma, and Wilms tumor in two patients each; and other tumor types in five patients.
  • SMNs occurred after a median of 8 years (range, 1.9-15.0 years) and included rhabdomyosarcoma (RMS) in 4 patients, malignant peripheral nerve sheath tumor in 4 patients, extraosseous Ewing family tumor (EFT) in 4 patients, leiomyosarcoma in 3 patients, fibrosarcoma in 2 patients, synovial sarcoma in 2 patients, and other tumor types in 6 patients.
  • Treatment generally was administered according to the guidelines for primary STS.
  • RESULTS: Seven non-RMS patients with STS underwent surgery alone, whereas 18 patients received chemotherapy and 8 patients received radiotherapy.
  • Fifteen patients were alive in complete remission of their SMN at the time of last follow-up.
  • Responses to chemotherapy and survival were satisfactory for patients with tumors such as RMS and EFT.
  • Complete tumor resection was correlated with a favorable prognosis in patients with other types of STS and in patients with postirradiation sarcoma.
  • Two patients developed a third malignancy.
  • CONCLUSIONS: Although prior treatment may hinder the management of these patients, pediatric STS second malignancies can be cured using the same strategies used for de novo pediatric sarcomas.
  • Long-term follow-up is mandatory given the risks of further malignancies and more severe, treatment-related side effects.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasms, Second Primary. Sarcoma / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Prognosis. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 American Cancer Society.
  • (PMID = 15073867.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


3. Dobashi Y, Suzuki S, Sato E, Hamada Y, Yanagawa T, Ooi A: EGFR-dependent and independent activation of Akt/mTOR cascade in bone and soft tissue tumors. Mod Pathol; 2009 Oct;22(10):1328-40
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EGFR-dependent and independent activation of Akt/mTOR cascade in bone and soft tissue tumors.
  • To gain the insight into the involvement of signaling mediated by the mammalian target of rapamycin (mTOR) in the phenotype and biological profiles of tumors and tumor-like lesions of the bone and soft tissue, we analyzed the expression and phosphorylation (activation) of mTOR and its correlation with the status of upstream and downstream modulator proteins Akt, p70S6-kinase (S6K), and eukaryotic initiation factor 4E-binding protein 1 (4E-BP1), which we refer to collectively as mTOR cassette proteins.
  • Immunohistochemical analysis of 140 cases showed activation of Akt in 55% (61% in malignant and 27% in benign), and mTOR expression in 61% (66% in malignant and 39% in benign).
  • The preponderance of mTOR activation was found in tumors of peripheral nerve sheath (malignant peripheral nerve sheath tumor and schwannoma), skeletal muscle origin (rhabdomyosarcoma), and in those exhibiting epithelial nature (chordoma and synovial sarcoma).
  • We conclude that mTOR-mediated signaling proteins function not only in the proliferation of the tumor cells, but also in the differentiation and/or maintenance of morphological phenotypes in tumors of rhabdomyoblastic and nerve sheath cell origin.
  • Overall, these results suggest that inhibitors of mTOR cassette may be useful as novel components of combined chemotherapy for a defined subset of bone and soft tissue sarcomas.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / analysis. Bone Neoplasms / enzymology. Phosphoproteins / analysis. Protein Kinases / analysis. Proto-Oncogene Proteins c-akt / analysis. Receptor, Epidermal Growth Factor / analysis. Ribosomal Protein S6 Kinases, 70-kDa / analysis. Signal Transduction. Soft Tissue Neoplasms / enzymology
  • [MeSH-minor] Cell Proliferation. Enzyme Activation. Humans. Immunoblotting. Immunohistochemistry. Mutation. Neoplasm Staging. Phosphorylation. Prognosis. TOR Serine-Threonine Kinases

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19648884.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / EIF4EBP1 protein, human; 0 / Phosphoproteins; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.1 / Ribosomal Protein S6 Kinases, 70-kDa
  •  go-up   go-down


Advertisement
4. Skubitz KM, Pambuccian S, Manivel JC, Skubitz AP: Identification of heterogeneity among soft tissue sarcomas by gene expression profiles from different tumors. J Transl Med; 2008 May 06;6:23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of heterogeneity among soft tissue sarcomas by gene expression profiles from different tumors.
  • The heterogeneity that soft tissue sarcomas (STS) exhibit in their clinical behavior, even within histological subtypes, complicates patient care.
  • Morphologic features are generally good predictors of biologic behavior, however, metastatic propensity, tumor growth, and response to chemotherapy may be determined by gene expression patterns that do not correlate well with morphology.
  • One approach to identify heterogeneity is to search for genetic markers that correlate with differences in tumor behavior.
  • In this study, gene expression in 53 samples of STS and AF [including 16 malignant fibrous histiocytoma (MFH), 9 leiomyosarcoma, 12 liposarcoma, 4 synovial sarcoma, and 12 samples of AF] was determined at Gene Logic Inc. (Gaithersburg, MD) using Affymetrix GeneChip U_133 arrays containing approximately 40,000 genes/ESTs.
  • In addition, several genes that are targets of some anti-tumor drugs were found to be differentially expressed in particular subsets of STS.

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1984 Feb 1;53(3):530-41 [6692258.001]
  • [Cites] J Lab Clin Med. 2004 Aug;144(2):78-91 [15322502.001]
  • [Cites] Cancer. 1986 Jul 15;58(2):306-9 [3719523.001]
  • [Cites] Cancer. 1988 Feb 15;61(4):817-23 [3338039.001]
  • [Cites] Cancer. 1988 Sep 1;62(5):994-8 [3409180.001]
  • [Cites] Am J Physiol. 1992 Dec;263(6 Pt 1):L627-33 [1476204.001]
  • [Cites] Ann N Y Acad Sci. 1992 Dec 4;667:101-11 [1309029.001]
  • [Cites] Mod Pathol. 1995 Sep;8(7):705-10 [8539226.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):350-62 [8996162.001]
  • [Cites] Am J Pathol. 1997 Aug;151(2):329-34 [9250146.001]
  • [Cites] J Surg Oncol. 1999 Oct;72(2):77-82 [10518103.001]
  • [Cites] Cancer Immun. 2005 Feb 1;5:2 [15683221.001]
  • [Cites] Cancer Invest. 2005;23(2):105-18 [15813502.001]
  • [Cites] N Engl J Med. 2005 Aug 18;353(7):701-11 [16107623.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9226-35 [16230383.001]
  • [Cites] Histopathology. 2006 Jan;48(1):22-31 [16359534.001]
  • [Cites] Histopathology. 2006 Jan;48(1):51-62 [16359537.001]
  • [Cites] J Clin Oncol. 2006 Mar 1;24(7):1195-203 [16505440.001]
  • [Cites] J Lab Clin Med. 2006 May;147(5):250-67 [16697773.001]
  • [Cites] Transl Res. 2006 Nov;148(5):223-48 [17145569.001]
  • [Cites] J Natl Compr Canc Netw. 2007 Apr;5(4):364-99 [17442230.001]
  • [Cites] Mayo Clin Proc. 2007 Nov;82(11):1409-32 [17976362.001]
  • [Cites] Annu Rev Pathol. 2006;1:119-50 [18039110.001]
  • [Cites] Cancer Cell. 2007 Dec;12(6):514-27 [18068629.001]
  • [Cites] Oncogene. 1999 Nov 11;18(47):6615-20 [10597266.001]
  • [Cites] J Clin Pathol. 1999 Sep;52(9):695-6 [10655994.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • [Cites] Int J Cancer. 2001 Mar 20;95(2):102-7 [11241320.001]
  • [Cites] Nat Med. 2001 Jun;7(6):673-9 [11385503.001]
  • [Cites] Breast Cancer Res. 2001;3(6):365-72 [11737887.001]
  • [Cites] Lab Invest. 2002 Jan;82(1):97-103 [11796830.001]
  • [Cites] Hum Pathol. 2002 Jan;33(1):39-46 [11823972.001]
  • [Cites] Lancet. 2002 Apr 13;359(9314):1301-7 [11965276.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):6973-8 [11983872.001]
  • [Cites] J Lab Clin Med. 2003 May;141(5):297-308 [12761473.001]
  • [Cites] Clin Cancer Res. 2003 Jun;9(6):1941-56 [12796356.001]
  • [Cites] Am J Pathol. 2003 Aug;163(2):691-700 [12875988.001]
  • [Cites] Cancer. 2003 Sep 1;98(5):1029-38 [12942572.001]
  • [Cites] J Lab Clin Med. 2004 Feb;143(2):89-98 [14966464.001]
  • [Cites] Clin Cancer Res. 2004 Jul 15;10(14):4776-83 [15269152.001]
  • [Cites] Cancer Immun. 2004 Aug 9;4:7 [15298487.001]
  • [Cites] J Clin Invest. 1985 Jan;75(1):11-8 [3965498.001]
  • (PMID = 18460215.001).
  • [ISSN] 1479-5876
  • [Journal-full-title] Journal of translational medicine
  • [ISO-abbreviation] J Transl Med
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA106878-03; United States / NCI NIH HHS / CA / R01 CA106878; United States / NCI NIH HHS / CA / R01 CA106878-03; United States / NCI NIH HHS / CA / R01CA106878
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Neoplasm
  • [Other-IDs] NLM/ PMC2412854
  •  go-up   go-down


5. Ayyoub M, Taub RN, Keohan ML, Hesdorffer M, Metthez G, Memeo L, Mansukhani M, Hibshoosh H, Hesdorffer CS, Valmori D: The frequent expression of cancer/testis antigens provides opportunities for immunotherapeutic targeting of sarcoma. Cancer Immun; 2004 Aug 9;4:7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sarcomas are rare but aggressive malignant tumors associated with high mortality, for which the efficacy of standard therapies remains limited.
  • In order to develop immunotherapeutic approaches for the treatment of sarcoma, we studied the relevance of cancer/testis antigens (CTAs), a group of antigens whose expression is developmentally regulated and that is specifically found in some tumor types, as sarcoma vaccine targets.
  • CTA expression was assessed by PCR and/or immunohistochemistry (IHC) in sarcoma tumor samples that included different histological subtypes and sarcoma cell lines.
  • Expression of HLA class I was assessed by IHC in tumor samples and by FACS analysis in cell lines.
  • More than 70% of the tumor samples expressed at least one CTA.
  • HLA class I expression in cell lines was enhanced upon treatment with IFN-gamma.
  • CTA expression was enhanced or induced by treatment with the demethylating agent 5-aza-2'-deoxycytidine, resulting in recognition by specific CTLs.
  • Interestingly, a spontaneous humoral and CD8+ T cellular response to the CTA NY-ESO-1 was detected in a synovial sarcoma patient.
  • Together, these findings strongly support the implementation of CTA-based immunotherapy of sarcoma as a means to improve the efficacy of the standard therapy.
  • [MeSH-major] Antigens, Neoplasm / biosynthesis. Azacitidine / analogs & derivatives. Sarcoma / immunology
  • [MeSH-minor] Antibodies, Neoplasm / blood. Antibodies, Neoplasm / immunology. Autoantigens / biosynthesis. Autoantigens / genetics. Cell Line, Tumor. DNA Methylation / drug effects. HLA-A2 Antigen / biosynthesis. HLA-A2 Antigen / genetics. Humans. Immunohistochemistry. Immunotherapy / methods. Interferon-gamma / pharmacology. Membrane Proteins / biosynthesis. Membrane Proteins / genetics. Neoplasm Proteins / biosynthesis. Neoplasm Proteins / genetics. Neoplasm Proteins / immunology. Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. AZACITIDINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15298487.001).
  • [ISSN] 1424-9634
  • [Journal-full-title] Cancer immunity
  • [ISO-abbreviation] Cancer Immun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / Antigens, Neoplasm; 0 / Autoantigens; 0 / CTAG1B protein, human; 0 / HLA-A2 Antigen; 0 / MAGEA3 protein, human; 0 / MAGEA4 protein, human; 0 / Membrane Proteins; 0 / Neoplasm Proteins; 776B62CQ27 / decitabine; 82115-62-6 / Interferon-gamma; M801H13NRU / Azacitidine
  •  go-up   go-down


6. Jacobs S, Fox E, Krailo M, Hartley G, Navid F, Wexler L, Blaney SM, Goodwin A, Goodspeed W, Balis FM, Adamson PC, Widemann BC: Phase II trial of ixabepilone administered daily for five days in children and young adults with refractory solid tumors: a report from the children's oncology group. Clin Cancer Res; 2010 Jan 15;16(2):750-4
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Ixabepilone is a microtubule-stabilizing agent with activity in adult solid tumors and in pediatric tumor xenograft models that are resistant to paclitaxel.
  • This study aimed to determine the response rate to ixabepilone in six solid tumor strata in children and young adults.
  • EXPERIMENTAL DESIGN: We conducted a phase II trial of ixabepilone (8 mg/m(2)/dose for 5 days every 21 days) using a two-stage design in taxane-naïve children and young adults with treatment-refractory, measurable rhabdomyosarcoma, Ewing sarcoma family tumors, osteosarcoma, synovial sarcoma, or malignant peripheral nerve sheath tumor, neuroblastoma, and Wilms tumor.
  • Seven patients received >or=3 cycles, and two had prolonged stable disease (Wilms' tumor, 38 cycles; synovial sarcoma, 8 cycles).

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Ixabepilone .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6950-8 [16203787.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 Jun-Jul;23(5):277-81 [11464982.001]
  • [Cites] J Clin Oncol. 2003 May 1;21(9):1866-73 [12721265.001]
  • [Cites] Clin Cancer Res. 2004 Feb 15;10(4):1289-98 [14977827.001]
  • [Cites] J Clin Oncol. 2004 May 15;22(10):2015-25 [15143095.001]
  • [Cites] J Clin Oncol. 1993 Dec;11(12):2324-9 [7902425.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1538-43 [9193350.001]
  • [Cites] Clin Cancer Res. 1999 Apr;5(4):733-7 [10213206.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2726-34 [15837987.001]
  • [Cites] Cancer. 2006 Apr 15;106(8):1821-8 [16532433.001]
  • [Cites] J Clin Oncol. 2007 Aug 10;25(23):3421-7 [17606971.001]
  • [Cites] J Clin Oncol. 2007 Aug 10;25(23):3415-20 [17606972.001]
  • [Cites] J Clin Oncol. 2007 Aug 10;25(23):3399-406 [17606975.001]
  • [Cites] Ann Oncol. 2007 Sep;18(9):1548-53 [17761711.001]
  • [Cites] Pediatr Blood Cancer. 2007 Dec;49(7):928-40 [17066459.001]
  • [Cites] Oncologist. 2008 Dec;13(12):1207-23 [19088324.001]
  • [Cites] J Clin Oncol. 2009 Feb 1;27(4):550-6 [19075272.001]
  • [Cites] Clin Cancer Res. 2001 May;7(5):1429-37 [11350914.001]
  • (PMID = 20068084.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA098413; United States / NCI NIH HHS / CA / U10 CA 98543; United States / Intramural NIH HHS / / ; United States / NCI NIH HHS / CA / U10 CA098543-08; None / None / / U10 CA098543-08; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / U10 CA098413-08; None / None / / U10 CA098413-08
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Epothilones; K27005NP0A / ixabepilone
  • [Other-IDs] NLM/ NIHMS160304; NLM/ PMC3086796
  •  go-up   go-down


7. Zhang PJ, Brooks JS, Goldblum JR, Yoder B, Seethala R, Pawel B, Gorman JH, Gorman RC, Huang JH, Acker M, Narula N: Primary cardiac sarcomas: a clinicopathologic analysis of a series with follow-up information in 17 patients and emphasis on long-term survival. Hum Pathol; 2008 Sep;39(9):1385-95
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although cardiac sarcomas are rare in comparison to their soft tissue counterparts, they are the second most common type of primary cardiac neoplasm.
  • There were 6 angiosarcomas, 6 myxofibrosarcomas, 3 malignant peripheral nerve sheath tumors, 3 leiomyosarcomas, 2 synovial sarcomas, 1 epithelioid hemangioendothelioma, 1 chondrosarcoma, 1 osteosarcoma, and 4 poorly differentiated sarcomas.
  • Six high-grade and 1 low-grade tumors were also treated with adjuvant chemotherapy and/or radiation.
  • In 17 patients with follow-up data, 6 of 12 patients with high-grade tumor died (4 within 5 days of the initial surgery, 1 in 21 months, and 1 in 131 months), and 1 patient with moderate-grade tumor and all 4 patients with low-grade tumor were alive without evidence of disease at the end of follow-up.
  • Tumor grade appeared to be prognostically important in cardiac sarcoma.
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Infant. Male. Middle Aged. Survival Analysis

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Thorac Surg. 2000 Jun;69(6):1949-51 [10892961.001]
  • [Cites] Z Kardiol. 2002 Apr;91(4):352-6 [12063709.001]
  • [Cites] J Heart Lung Transplant. 2002 Oct;21(10):1135-9 [12398881.001]
  • [Cites] Rev Esp Cardiol. 2003 Apr;56(4):408-11 [12689577.001]
  • [Cites] Chest. 2003 May;123(5):1766-8 [12740300.001]
  • [Cites] Thorac Cardiovasc Surg. 2004 Apr;52(2):77-81 [15103579.001]
  • [Cites] Ann Surg. 1980 Feb;191(2):127-38 [7362282.001]
  • [Cites] Hum Pathol. 1982 Jul;13(7):640-5 [7084941.001]
  • [Cites] Cancer. 1984 Feb 1;53(3):530-41 [6692258.001]
  • [Cites] Arch Pathol Lab Med. 1985 Oct;109(10):943-5 [3840005.001]
  • [Cites] Chest. 1987 Jul;92(1):177-9 [3595230.001]
  • [Cites] Chest. 1987 Nov;92(5):860-2 [3665601.001]
  • [Cites] Thorac Cardiovasc Surg. 1990 Aug;38 Suppl 2:183-91 [2237900.001]
  • [Cites] Thorac Cardiovasc Surg. 1990 Aug;38 Suppl 2:192-5 [2237901.001]
  • [Cites] Ann Thorac Surg. 1991 Jun;51(6):906-10 [2039319.001]
  • [Cites] Ann Thorac Surg. 1991 Jun;51(6):999-1001 [2039335.001]
  • [Cites] Ann Thorac Surg. 1991 Oct;52(4):886-95 [1929651.001]
  • [Cites] Cancer. 1992 Jan 15;69(2):387-95 [1728367.001]
  • [Cites] Am Heart J. 1992 Jan;123(1):232-4 [1729836.001]
  • [Cites] Aust N Z J Med. 1991 Dec;21(6):881-3 [1818549.001]
  • [Cites] Scand J Thorac Cardiovasc Surg. 1992;26(3):233-6 [1287840.001]
  • [Cites] J Cardiovasc Surg (Torino). 1993 Dec;34(6):529-33 [8300722.001]
  • [Cites] Semin Surg Oncol. 1994 Sep-Oct;10(5):374-82 [7997732.001]
  • [Cites] J Heart Lung Transplant. 1995 Mar-Apr;14(2):382-6 [7779860.001]
  • [Cites] Hum Mol Genet. 1995 Jun;4(6):1097-9 [7655467.001]
  • [Cites] Histopathology. 1997 Apr;30(4):349-52 [9147083.001]
  • [Cites] Jpn Circ J. 1997 Sep;61(9):795-7 [9293411.001]
  • [Cites] Ann Diagn Pathol. 1998 Jun;2(3):167-72 [9845736.001]
  • [Cites] Br J Cancer. 1998 Dec;78(12):1624-8 [9862574.001]
  • [Cites] J Surg Oncol. 1999 Mar;70(3):194-8 [10102352.001]
  • [Cites] Histopathology. 1999 Apr;34(4):295-304 [10231396.001]
  • [Cites] Eur J Cardiothorac Surg. 2006 Jun;29(6):925-32 [16675225.001]
  • [Cites] J Thorac Oncol. 2006 Feb;1(2):188-9 [17409853.001]
  • [Cites] Gen Thorac Cardiovasc Surg. 2007 Jan;55(1):19-22 [17444167.001]
  • [Cites] Oncologist. 2007 Sep;12(9):1134-42 [17914083.001]
  • (PMID = 18602663.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL063954
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS522251; NLM/ PMC4081532
  •  go-up   go-down


8. Ford ME, Stevens R, Rosado-de-Christenson ML, Hall NC, Suster S: Rebound thymic hyperplasia after pneumonectomy and chemotherapy for primary synovial sarcoma. J Thorac Imaging; 2008 Aug;23(3):178-81
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rebound thymic hyperplasia after pneumonectomy and chemotherapy for primary synovial sarcoma.
  • Thymic hyperplasia occurs in a small proportion of patients receiving chemotherapy for various malignancies.
  • Fluorodeoxyglucose positron emission tomography-computed tomography is an important tool for staging malignant neoplasms.
  • We report a case of rebound thymic hyperplasia manifesting as a hypermetabolic mass on fluorodeoxyglucose positron emission tomography-computed tomography after pneumonectomy and chemotherapy for primary pulmonary synovial sarcoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Pneumonectomy. Sarcoma, Synovial / drug therapy. Sarcoma, Synovial / surgery. Thymus Hyperplasia / therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Doxorubicin / therapeutic use. Humans. Ifosfamide / therapeutic use. Male. Neoplasm Recurrence, Local / complications. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Positron-Emission Tomography. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • Genetic Alliance. consumer health - Thymic hyperplasia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18728544.001).
  • [ISSN] 1536-0237
  • [Journal-full-title] Journal of thoracic imaging
  • [ISO-abbreviation] J Thorac Imaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


9. Stage AC, Pollock RE, Matin SF: Bilateral metastatic renal synovial sarcoma. Urology; 2005 Feb;65(2):389
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral metastatic renal synovial sarcoma.
  • Synovial sarcoma is a malignant soft-tissue neoplasm, usually arising in close association with the joints and generally carrying a poor prognosis.
  • We describe the first report of bilateral renal metastases from synovial sarcoma in a long-term survivor.
  • Treatment consisted of systemic therapy with bilateral partial nephrectomies.
  • [MeSH-major] Forearm. Kidney Neoplasms / secondary. Sarcoma, Synovial / secondary. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Amputation. Antineoplastic Agents, Alkylating / therapeutic use. Combined Modality Therapy. Female. Humans. Ifosfamide / therapeutic use. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Middle Aged. Nephrectomy / methods

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15708068.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; UM20QQM95Y / Ifosfamide
  • [Number-of-references] 3
  •  go-up   go-down


10. Caliandro R, Terrier P, Regnard JF, De Montpréville V, Ruffié P: [Primary biphasic synovial sarcoma of the pleura]. Rev Mal Respir; 2000 Apr;17(2):498-502
Genetic Alliance. consumer health - Synovial sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary biphasic synovial sarcoma of the pleura].
  • A 36-year-old man presented with a pleural tumor.
  • The first pathologic analysis diagnosed biphasic pleural malignant mesothelioma.
  • However, the atypical clinical course, the early development of lung metastases and a new reading of histologic documents led to the diagnosis of primary pleural synovial sarcoma.
  • Because the efficacy of chemotherapy and/or radiotherapy is poor, surgery remains the basis of treatment, whenever possible.
  • [MeSH-major] Pleural Neoplasms / pathology. Sarcoma, Synovial / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Immunohistochemistry. Lung Neoplasms / secondary. Male. Mesothelioma / pathology. Neoplasm Recurrence, Local / pathology. Prognosis. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10859770.001).
  • [ISSN] 0761-8425
  • [Journal-full-title] Revue des maladies respiratoires
  • [ISO-abbreviation] Rev Mal Respir
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] FRANCE
  • [Number-of-references] 14
  •  go-up   go-down


11. Fresneau B, Oberlin O, Brugières L, Valteau-Couanet D, Patte C: [Malignant primary cardiac tumors in childhood and adolescence]. Arch Pediatr; 2010 May;17(5):495-501

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant primary cardiac tumors in childhood and adolescence].
  • The majority of them are benign, with only 10% malignant.
  • Among malignant cardiac tumors, sarcoma (rhabdomyosarcoma, angiosarcoma, synovial sarcoma) and lymphoma (Burkitt's lymphoma, large B-cell lymphoma, lymphoblastic lymphoma) predominate.
  • There are few published pediatric series on malignant primary cardiac tumors.
  • We report here 3 observations of primary malignant cardiac tumors, 2 cases of sarcoma (angiosarcoma and synovial sarcoma) and 1 case of Burkitt's lymphoma.
  • For sarcoma, treatment associates surgery and chemotherapy.
  • Surgery should be as complete as possible because of the lack of chemotherapy sensitivity of some sarcomas, mainly angiosarcoma and synovial sarcoma.
  • Chemotherapy is the main treatment, and surgery has to be used only when complications occur.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Heart Neoplasms / diagnosis. Hemangiosarcoma / diagnosis. Sarcoma, Synovial / diagnosis
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Cough / etiology. Diagnosis, Differential. Dyspnea / etiology. Echocardiography. Fatal Outcome. Female. Heart Atria / pathology. Heart Atria / surgery. Humans. Male. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / pathology. Neoplasm, Residual / diagnosis. Neoplasm, Residual / pathology. Pulmonary Heart Disease / diagnosis. Pulmonary Heart Disease / etiology. Superior Vena Cava Syndrome / diagnosis. Superior Vena Cava Syndrome / etiology. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20338733.001).
  • [ISSN] 1769-664X
  • [Journal-full-title] Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie
  • [ISO-abbreviation] Arch Pediatr
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


12. Mitsuhashi A, Nagai Y, Suzuka K, Yamazawa K, Nojima T, Nikaido T, Ishikura H, Matsui H, Shozu M: Primary synovial sarcoma in fallopian tube: case report and literature review. Int J Gynecol Pathol; 2007 Jan;26(1):34-7
Genetic Alliance. consumer health - Synovial sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary synovial sarcoma in fallopian tube: case report and literature review.
  • Synovial sarcoma, a malignant mesenchymal neoplasm, occurs mostly near the joints of the extremities and occasionally outside the joint such as lung.
  • We report a case of soft tissue sarcoma arising in the fallopian tube origin that showed characteristic pathological appearance of biphasic synovial sarcoma.
  • Molecular analysis detected a fusion gene transcript of synovial sarcoma translocation (SYT) gene from chromosome 18 and synovial sarcoma X chromosome breakpoint 1 (SSX1) gene, which is believed to pathognomonic for synovial sarcoma of joint origin.
  • Recurrent abdominal tumor, observed at 12 month after the initial surgery and following chemotherapy using doxorubicin, cisplatin and ifosfamide, partially responded to chemotherapy using paclitaxel and carboplatin and, then, optimal surgery was performed.
  • This is the first report of a synovial sarcoma arising in the fallopian tube.
  • [MeSH-major] Fallopian Tube Neoplasms / pathology. Sarcoma, Synovial / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17197895.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion; 0 / SYT-SSX fusion protein
  • [Number-of-references] 12
  •  go-up   go-down


13. Artico R, Bison E, Brotto M: Monophasic synovial sarcoma of hypopharynx: case report and review of the literature. Acta Otorhinolaryngol Ital; 2004 Feb;24(1):33-6
Genetic Alliance. consumer health - Synovial sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monophasic synovial sarcoma of hypopharynx: case report and review of the literature.
  • Synovial sarcoma (SS) is a malignant mesenchymal neoplasm usually involving the lower limbs of young adults.
  • Treatment options include an aggressive surgical approach and radiotherapy, whereas the role of chemotherapy remains to be defined.
  • The case is described of monophasic synovial sarcoma located in the hypopharynx and a review is made of the literature concerning this rare neoplasm.
  • [MeSH-major] Hypopharyngeal Neoplasms / pathology. Hypopharyngeal Neoplasms / radiography. Sarcoma, Synovial / pathology. Sarcoma, Synovial / radiography
  • [MeSH-minor] Adult. Humans. Male. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15270432.001).
  • [ISSN] 0392-100X
  • [Journal-full-title] Acta otorhinolaryngologica Italica : organo ufficiale della Società italiana di otorinolaringologia e chirurgia cervico-facciale
  • [ISO-abbreviation] Acta Otorhinolaryngol Ital
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 22
  •  go-up   go-down


14. Krieghoff B, Skuballa A, Leonhardt P, Mohr FW, Wittekind C, Bossert T, Achatzy R: [Primary synovial sarcoma of the lung - a rare tumor]. Zentralbl Chir; 2002 Aug;127(8):716-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary synovial sarcoma of the lung - a rare tumor].
  • We present a 26 year old patient with a primary malignant synovial sarcoma of the lung that was observed for more than one year by a general practitioner and a pulmologist.
  • Finally, because of recurrent hemoptysis a central tumor of mesenchymal origin of the left lower lobe was diagnosed by bronchoscopy.
  • In the postoperative course the patient underwent chemo-therapy, 6 cycles adriablastine/ifosfamid.
  • 8 months after the first operation an extensive tumor recurrency occurred with infiltration of the chest wall.
  • The patient refused further radio- or chemotherapy and died 14 months after the operation.
  • Because of the small number of cases therapeutic strategy conceptions do not exist.
  • The resection of the tumor is generally recommended.
  • Chemo- and radiotherapy are accepted as an option for advanced tumor stage.
  • [MeSH-major] Lung Neoplasms / surgery. Sarcoma, Synovial / surgery
  • [MeSH-minor] Adult. Bronchoscopy. Diagnosis, Differential. Diagnostic Imaging. Humans. Lung / pathology. Male. Neoplasm Staging. Pneumonectomy

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12200737.001).
  • [ISSN] 0044-409X
  • [Journal-full-title] Zentralblatt für Chirurgie
  • [ISO-abbreviation] Zentralbl Chir
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


15. Andrassy RJ, Okcu MF, Despa S, Raney RB: Synovial sarcoma in children: surgical lessons from a single institution and review of the literature. J Am Coll Surg; 2001 Mar;192(3):305-13
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synovial sarcoma in children: surgical lessons from a single institution and review of the literature.
  • BACKGROUND: Synovial sarcomas are malignant high-grade, soft-tissue neoplasms that account for 7% to 8% of all malignant soft-tissue tumors and are the most common nonrhabdomyosarcoma soft-tissue sarcomas in pediatric patients.
  • STUDY DESIGN: A retrospective review of the records of children younger than 17 years with synovial sarcoma treated at the University of Texas MD Anderson Cancer Center from 1966 until 1999 was undertaken.
  • Primary site, tumor size, tumor margins, surgical treatment, adjuvant therapy, local and distant recurrence, and survival were recorded for 42 patients.
  • Eleven patients were dead and four others had progressed but were alive without evidence of disease after further therapy.
  • Intergroup Rhabdomyosarcoma Study (IRS) grouping and tumor invasiveness were found to be significant prognostic indicators (p < 0.01 and p = 0.02, respectively).
  • Adjuvant radiation therapy appeared to be of benefit, and chemotherapy did not seem to impact PFS or OS.
  • CONCLUSIONS: Complete resection with clear, yet not necessarily large, margins remains the treatment of choice for synovial sarcoma in children.
  • Adjuvant radiation therapy should possibly be considered in patients with clear margins (IRS Group I) and in patients with microscopic residual tumor (IRS Group II).
  • Chemotherapy did not seem to impact PFS or OS.
  • [MeSH-major] Sarcoma, Synovial / pathology. Sarcoma, Synovial / surgery
  • [MeSH-minor] Adolescent. Age Distribution. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cancer Care Facilities. Child. Child, Preschool. Disease-Free Survival. Female. Hospitals, University. Humans. Male. Neoplasm Recurrence, Local / etiology. Patient Selection. Prognosis. Proportional Hazards Models. Radiotherapy, Adjuvant. Retrospective Studies. Texas / epidemiology. Treatment Outcome

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11245372.001).
  • [ISSN] 1072-7515
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 17
  •  go-up   go-down


16. Ravnik J, Potrc S, Kavalar R, Ravnik M, Zakotnik B, Bunc G: Dumbbell synovial sarcoma of the thoracolumbar spine: a case report. Spine (Phila Pa 1976); 2009 May 1;34(10):E363-6
Genetic Alliance. consumer health - Synovial sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dumbbell synovial sarcoma of the thoracolumbar spine: a case report.
  • STUDY DESIGN: A case report is of a giant dumbbell-shaped synovial sarcoma of the thoracolumbar spine is presented.
  • OBJECTIVE: To report a case of a rare dumbbell-shaped tumor treated by multimodal approach.
  • Surgical procedures, adjuvant treatment, and outcome were discussed.
  • SUMMARY OF BACKGROUND DATA: Synovial sarcomas of the spine are very rare tumors.
  • Dumbbell-shaped spinal synovial sarcoma with a giant extraspinal extension has not yet been reported.
  • The rationale for 2-step surgical procedure and adjuvant therapy is discussed in light of the clinical picture, preoperative imaging and extension of the disease.
  • A dumbbell-shaped tumor at the level Th12-L1 was found with a giant retroperitoneal extension.
  • Tumor was nonradically excised in a 2-step operation: first through a dorsal approach with laminectomy and removal of the intraspinal extradural part, and later through a laparotomy with removal of the retroperitoneal part.
  • Histologic examination revealed highly malignant synovial sarcoma.
  • Patient was treated with chemotherapy and radiotherapy after surgery.
  • RESULTS: Patient was in remission and symptom free for 1 year after surgery; he then developed a local recurrence and died soon afterwards.
  • CONCLUSION: A good treatment result was achieved initially.
  • A combined approach in cases like this is warranted, with as radical surgery as possible in order to avoid local recurrence, a common cause of treatment failure in sarcomas.
  • [MeSH-major] Lumbar Vertebrae / pathology. Neurosurgical Procedures / methods. Retroperitoneal Neoplasms / secondary. Sarcoma, Synovial / secondary. Spinal Neoplasms / pathology. Thoracic Vertebrae / pathology
  • [MeSH-minor] Adult. Epidural Space / pathology. Epidural Space / radiography. Epidural Space / surgery. Fatal Outcome. Humans. Laminectomy. Laparotomy. Magnetic Resonance Imaging. Male. Neoplasm Recurrence, Local. Paraparesis / etiology. Retroperitoneal Space / pathology. Retroperitoneal Space / radiography. Retroperitoneal Space / surgery. Spinal Canal / pathology. Spinal Canal / radiography. Spinal Canal / surgery. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19404166.001).
  • [ISSN] 1528-1159
  • [Journal-full-title] Spine
  • [ISO-abbreviation] Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Murray PM: Soft tissue sarcoma of the upper extremity. Hand Clin; 2004 Aug;20(3):325-33, vii
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soft tissue sarcoma of the upper extremity.
  • Soft tissue sarcomas of the upper extremities are rare and hand surgeons typically encounter only one or two undiagnosed soft tissue sarcomas during their careers.
  • It is incumbent on the physician to review repeatedly the characteristics of these tumors and remain suspicious, because these lesions typically are misdiagnosed and treatment is delayed.
  • The most common soft tissue sarcomas of the upper extremity are the epithelioid sarcoma, synovial cell sarcoma, and malignant fibrous histiocytoma.
  • Limb salvage surgery is the treatment of choice for soft tissue sarcomas to preserve upper extremity function.
  • Following wide tumor resection, adjuvant therapies such as chemotherapy, external beam radiation therapy, and brachytherapy may lessen local recurrence rates, but their effect on overall survival remains unclear.
  • [MeSH-major] Sarcoma. Soft Tissue Neoplasms
  • [MeSH-minor] Arm. Biopsy. Chemotherapy, Adjuvant. Dermatofibrosarcoma / diagnosis. Dermatofibrosarcoma / surgery. Fibrosarcoma / pathology. Fibrosarcoma / therapy. Histiocytoma, Benign Fibrous / mortality. Histiocytoma, Benign Fibrous / pathology. Humans. Liposarcoma / pathology. Neoplasm Metastasis. Neoplasm Recurrence, Local. Prognosis. Rhabdomyosarcoma / pathology. Rhabdomyosarcoma / therapy. Sarcoma, Clear Cell / diagnosis. Sarcoma, Synovial / diagnosis

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15275691.001).
  • [ISSN] 0749-0712
  • [Journal-full-title] Hand clinics
  • [ISO-abbreviation] Hand Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 46
  •  go-up   go-down


18. Zawitkowska-Klaczyńska J, Katski K, Woźniak M, Kowalczyk JR: Characteristics and outcome of children with primary soft tissue sarcomas of extremities. Med Wieku Rozwoj; 2004 Apr-Jun;8(2 Pt 1):169-74
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics and outcome of children with primary soft tissue sarcomas of extremities.
  • OBJECTIVES: To determine the characteristics and outcome or patients with primary soft tissue sarcomas of extremities in children.
  • MATERIAL AND METHODS: Thirty-six patients treated for soft tissues sarcomas were enrolled into the study.
  • Features analysed: the incidence of soft tissues sarcoma of extremities, the time from first clinical symptoms to making the diagnosis, the primary site of tumour; histopathologic type of tumour, stage of disease, methods and results of the treatment.
  • RESULTS: The time From first symptoms to making the diagnosis was 5.4 months (mean).
  • Histopathologic types: synovial sarcoma in 4 patients, malignant haemangiopericytoma in 2, rhabdomyosarcoma in 2, sarcoma myogenes in 1, primitive neuroectodermal tumour in l.
  • Patients underwent treatment according to the soft tissue sarcoma protocols.
  • Results of treatment: first complete remission was observed in 7 patients; second complete remission in 1, one patient is on postoperative treatment.
  • Combined treatment achieves full remission in the majority of patients with soft tissues sarcomas localized within the limbs.
  • 2. In patients with large tumours (>5 cm) the treatment should to be started with inductive chemotherapy, and the surgery should be postponed.
  • 3. Early excision of the tumour should be considered in cases of small tumours (< 5 cm), when resection with wide margin of healthy tissues is possible, without deteriorating the function of the limb or cosmetic damage.
  • [MeSH-major] Arm. Leg. Sarcoma / diagnosis. Sarcoma / therapy
  • [MeSH-minor] Adolescent. Chemotherapy, Adjuvant. Child. Disease-Free Survival. Female. Hemangiopericytoma / diagnosis. Hemangiopericytoma / therapy. Humans. Incidence. Male. Myosarcoma / diagnosis. Myosarcoma / therapy. Neoplasm Staging. Neuroectodermal Tumors / diagnosis. Neuroectodermal Tumors / therapy. Poland / epidemiology. Retrospective Studies. Rhabdomyosarcoma / diagnosis. Rhabdomyosarcoma / therapy. Sarcoma, Synovial / diagnosis. Sarcoma, Synovial / therapy. Survival Analysis. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15738590.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


19. Koscielniak E, Morgan M, Treuner J: Soft tissue sarcoma in children: prognosis and management. Paediatr Drugs; 2002;4(1):21-8
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soft tissue sarcoma in children: prognosis and management.
  • Soft tissue sarcomas (STS) account for approximately 7% of malignant neoplasms in children.
  • The heterogeneity of STS makes the diagnosis and therapy particularly difficult and should be reserved for specialized centers with expertise in treating cancer in children.
  • Major progress in the accuracy of diagnosis and classification has been made by the identification of specific, recurring genetic alterations t(2;13)(q35;q14) and t(1;13)(p36;q14) in alveolar rhabdomyosarcomas (RMS), t(X;18)(p11;q11) for synovial sarcoma (SS) and t(11;22)(q24;q12) or t(21;22)(q22;q12) for Ewing's tumor family.
  • As a result of large multicenter STS studies, such as the North-American Intergroup Rhabdomyosarcoma Study, the German Pediatric Soft Tissue Sarcoma Study Group (CWS), Italian Gruppo Cooperativo Italiano study and Sociètè Internationale d'Oncologie Pèdiatrique (SIOP) Malignant Mesenchymal Tumors study, the identification of more effective treatment strategies and improvement in prognosis have been made in the last 30 years.
  • Prognostic variables were identified and, by exploring novel therapeutic strategies, criteria were established for the use of preoperative chemotherapy and radiotherapy, and primary and delayed second-look surgery.
  • As a result of evaluation of different drugs active in STS, refinements in the utilization of chemotherapy have been made possible.
  • Clinical trials have also been instrumental in defining the late effects of treatment.
  • In STS the following drugs have proven to be useful: dactinomycin, vincristine, alkylating agents such as cyclophosphamide and ifosfamide, as well as anthracyclines such as doxorubicin (adriamycin) and epi-doxorubicin.
  • In general, with conventional fractionation (1 x 1.8 to 2 Gy/day) radiotherapy doses between 40 and 50 Gy should be administered.
  • The German CWS group explored the effectiveness of 32 Gy when accelerated and hyperfractionated, and given simultaneously to chemotherapy, and found it adequate for local tumor control in patients with selected favorable prognostic factors.
  • When treated with a combination of chemotherapy and local therapy, STS showed an event-free survival between 50 and 80% [RMS 70%, extraskeletal Ewing sarcoma (EES) and peripheral neuroectodermal tumor (PNET) circa 50%, and SS 70 to 80%].
  • The value of high dose chemotherapy with hematopoietic stem cell rescue in patients with poor prognostic STS remains unclear and should be performed in controlled studies only.
  • [MeSH-major] Sarcoma / diagnosis. Soft Tissue Neoplasms / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols. Child. Combined Modality Therapy. Humans. Neoplasm Staging. Prognosis. Radiotherapy. Rhabdomyosarcoma / diagnosis. Rhabdomyosarcoma / surgery. Rhabdomyosarcoma / therapy

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1997 May;15(5):1831-6 [9164192.001]
  • [Cites] J Pediatr Hematol Oncol. 1997 Nov-Dec;19(6):483-91 [9407933.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 May;23(4):215-20 [11846299.001]
  • [Cites] Pediatr Transplant. 1999;3 Suppl 1:52-8 [10587972.001]
  • [Cites] Med Pediatr Oncol. 1998 May;30(5):269-75 [9544222.001]
  • [Cites] J Clin Oncol. 2001 Jun 1;19(11):2812-20 [11387352.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1052-6 [11287975.001]
  • [Cites] Acta Orthop Scand Suppl. 1999 Jun;285:8-10 [10429615.001]
  • [Cites] Cancer. 1995 Sep 15;76(6):1073-85 [8625211.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1544-52 [9193351.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):945-52 [9508177.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3706-19 [10577842.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):204-13 [10623711.001]
  • [Cites] N Engl J Med. 1991 Mar 21;324(12):808-15 [1997853.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2796-803 [10561355.001]
  • [Cites] N Engl J Med. 1999 Jul 29;341(5):342-52 [10423470.001]
  • [Cites] J Clin Oncol. 1993 Feb;11(2):262-70 [8426203.001]
  • [Cites] J Pediatr Hematol Oncol. 2000 Mar-Apr;22(2):112-8 [10779023.001]
  • [Cites] Bone Marrow Transplant. 1997 Feb;19(3):227-31 [9028550.001]
  • [Cites] N Engl J Med. 2000 Sep 14;343(11):750-8 [10984562.001]
  • [Cites] J Clin Oncol. 1990 Mar;8(3):443-52 [2407808.001]
  • [Cites] J Clin Oncol. 1996 Oct;14(10):2653-65 [8874324.001]
  • [Cites] Curr Opin Oncol. 1994 Jul;6(4):397-402 [7803541.001]
  • [Cites] Eur J Cancer. 1998 Jun;34(7):1050-62 [9849454.001]
  • [Cites] J Clin Oncol. 2001 Jun 15;19(12):3091-102 [11408506.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):610-30 [7884423.001]
  • [Cites] Med Pediatr Oncol. 1991;19(2):89-95 [2011101.001]
  • [Cites] Acta Orthop Scand Suppl. 1999 Jun;285:30-40 [10429619.001]
  • [Cites] Cancer. 1992 Nov 15;70(10):2557-67 [1482503.001]
  • [Cites] Arch Orthop Trauma Surg. 2000;120(1-2):65-9 [10653107.001]
  • [Cites] Klin Padiatr. 1999 Jul-Aug;211(4):291-5 [10472564.001]
  • (PMID = 11817983.001).
  • [ISSN] 1174-5878
  • [Journal-full-title] Paediatric drugs
  • [ISO-abbreviation] Paediatr Drugs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


20. Eilber FC, Eilber KS, Eilber FR: Retroperitoneal sarcomas. Curr Treat Options Oncol; 2000 Aug;1(3):274-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Imaging of the abdomen and pelvis by computed tomography (CT) provides both an imaging modality and a method by which to obtain tissue for diagnosis.
  • Because a histologic diagnosis is essential in treatment planning, adequate tissue can usually be obtained by a CT-guided core biopsy.
  • The treatment options for primary retroperitoneal sarcomas include chemotherapy, radiation therapy, surgery, or a combination of these modalities; therefore, a multidisciplinary group best manages treatment planning.
  • Primary radiation therapy for cure is seldom effective for retroperitoneal sarcomas but can provide palliation in select cases.
  • Systemic chemotherapy for chemosensitive lesions, such as poorly differentiated liposarcoma, malignant fibrous histiocytoma (MFH), synovial cell sarcoma, and primitive neuroectodermal tumors (PNET), can be useful when used in a neoadjuvant manner.
  • Consequently, surgical resection continues to be the mainstay of treatment for retroperitoneal sarcomas and requires en bloc resection of the primary tumor.
  • Postoperative adjuvant therapy with chemotherapy or radiation has not been proven to be of any additional benefit.
  • Overall treatment results are predominantly influenced by tumor stage, grade, size, and margins of surgical resection.
  • [MeSH-major] Retroperitoneal Neoplasms / therapy. Sarcoma / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Biopsy / methods. Clinical Trials as Topic. Combined Modality Therapy. Humans. Neoplasm Recurrence, Local / pathology. Radiotherapy. Survival Rate

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Coll Surg. 1996 Apr;182(4):329-39 [8605556.001]
  • [Cites] Surg Oncol. 1998 Jul-Aug;7(1-2):77-81 [10421510.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1600-8 [7541449.001]
  • [Cites] Cancer. 1999 Mar 1;85(5):1077-83 [10091791.001]
  • [Cites] Arch Surg. 1991 Mar;126(3):328-34 [1998475.001]
  • [Cites] J Clin Oncol. 1990 Jan;8(1):170-8 [2104923.001]
  • [Cites] Ann Surg. 1998 Sep;228(3):355-65 [9742918.001]
  • [Cites] J Clin Oncol. 1997 Aug;15(8):2832-9 [9256126.001]
  • [Cites] Cancer. 1977 May;39(5):1940-8 [858124.001]
  • [Cites] Ann Intern Med. 1982 Feb;96(2):133-9 [7059060.001]
  • [Cites] Cancer. 1994 May 15;73(10):2506-11 [8174046.001]
  • [Cites] Ann Surg. 1991 Jul;214(1):2-10 [2064467.001]
  • [Cites] Ann Surg. 1995 Feb;221(2):185-95 [7857146.001]
  • [Cites] Adv Surg. 1997;31:395-420 [9408503.001]
  • [Cites] Br J Surg. 1991 Aug;78(8):912-6 [1913104.001]
  • [Cites] Oncology (Williston Park). 1996 Dec;10(12):1867-72; discussion 1872-4 [8985970.001]
  • [Cites] Arch Surg. 1993 Apr;128(4):402-10 [8457152.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jul 30;29(5):1005-10 [8083069.001]
  • [Cites] Semin Oncol. 1997 Oct;24(5):526-33 [9344318.001]
  • (PMID = 12057171.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 21
  •  go-up   go-down


21. Benesch M, Windelberg M, Sauseng W, Witt V, Fleischhack G, Lackner H, Gadner H, Bode U, Urban C: Compassionate use of bevacizumab (Avastin) in children and young adults with refractory or recurrent solid tumors. Ann Oncol; 2008 Apr;19(4):807-13
MedlinePlus Health Information. consumer health - Cancer in Children.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: Fifteen patients (male: n = 8; female: n = 7; median age, 14.6 years) received bevacizumab for recurrent or progressive solid tumors (carcinoma: n = 3; neuroblastoma: n = 2; astrocytoma grade III: n = 2; rhabdomyosarcoma: n = 2; nephroblastoma: n = 2; benign vascular tumors: n = 2; synovial sarcoma: n = 1; and malignant hemangiopericytoma: n = 1) on a compassionate basis.
  • Most patients received chemotherapy in addition to bevacizumab.
  • Duration of bevacizumab therapy ranged from 1.5 to 23 months.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18056650.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


22. McGrory JE, Pritchard DJ, Arndt CA, Nascimento AG, Remstein ED, Rowland CM: Nonrhabdomyosarcoma soft tissue sarcomas in children. The Mayo Clinic experience. Clin Orthop Relat Res; 2000 May;(374):247-58
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nonrhabdomyosarcoma soft tissue sarcomas in children. The Mayo Clinic experience.
  • Eighty-six children to 18 years of age were treated for nonrhabdomyosarcoma soft tissue sarcomas of the trunk and extremities.
  • Synovial sarcoma (31), fibrosarcoma (13), malignant fibrous histiocytoma (11), epithelioid sarcoma (10), and clear cell sarcoma (7) were the most common diagnoses.
  • Patients were treated with wide removal of the tumor when possible, with judicious use of adjuvant radiation, or with chemotherapy in selected cases.
  • When compared with published data in adults, the prognosis of primary, localized nonrhabdomyosarcoma soft tissue sarcomas in children appears to be more favorable.
  • [MeSH-major] Fibrosarcoma / pathology. Fibrosarcoma / therapy. Histiocytoma, Benign Fibrous / pathology. Histiocytoma, Benign Fibrous / surgery. Sarcoma / pathology. Sarcoma / surgery. Sarcoma, Clear Cell / pathology. Sarcoma, Clear Cell / surgery. Sarcoma, Synovial / pathology. Sarcoma, Synovial / surgery. Soft Tissue Neoplasms / pathology. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adolescent. Age Factors. Biopsy. Chemotherapy, Adjuvant. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Infant. Male. Neoplasm Staging. Prognosis. Radiotherapy, Adjuvant. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10818984.001).
  • [ISSN] 0009-921X
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


23. Etienne-Mastroianni B, Falchero L, Chalabreysse L, Loire R, Ranchère D, Souquet PJ, Cordier JF: Primary sarcomas of the lung: a clinicopathologic study of 12 cases. Lung Cancer; 2002 Dec;38(3):283-9
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To study patients with primary sarcomas of the lung diagnosed in our pathology department in order to define their clinical characteristics, treatment, and prognosis.
  • The histologic diagnoses confirmed in all cases by detailed immunohistochemical study were leiomyosarcoma (7), monophasic synovial sarcoma (2), one case each of malignant peripheral nerve sheath tumor (MPNST), epithelioid sarcoma, and malignant fibrous histiocytoma.
  • Four patients received chemotherapy and two patients had radiation therapy postoperatively.
  • Treatment and prognosis do not differ from other soft tissue sarcomas.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12445750.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


24. Fang Z, Matsumoto S, Ae K, Kawaguchi N, Yoshikawa H, Ueda T, Ishii T, Araki N, Kito M: Postradiation soft tissue sarcoma: a multiinstitutional analysis of 14 cases in Japan. J Orthop Sci; 2004;9(3):242-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postradiation soft tissue sarcoma: a multiinstitutional analysis of 14 cases in Japan.
  • Radiation therapy (RT) is commonly used to treat malignant tumors, but it leads to side effects and complications.
  • This article focuses on the clinical manifestations, pathological characteristics, and therapeutic effects concerning postradiation soft tissue sarcomas (PRSTSs).
  • Their histological types were malignant fibrous histiocytoma (eight cases), extraskeletal osteosarcoma (four cases), fibrosarcoma (one case), and leiomyosarcoma (one case).
  • The primary diagnoses, RT history, latent period, and outcome of treatment were studied retrospectively.
  • The original tumors included uterine cancer (seven cases), breast cancer (four cases), synovial sarcoma (one case), squamous cell carcinoma (one case), and Hodgkin's disease (one case).
  • There were 13 women and 1 man, with ages ranging from 23 to 77 years (mean 58 years) at the time of the appearance of the PRSTS.
  • RT doses ranged from 48 to 91 Gy (mean 62 Gy).
  • One of three who underwent RT and one of five who underwent chemotherapy (CT) responded.
  • The prognosis of the PRSTS patients was not poor if the tumor could be removed with a wide surgical margin.
  • Because adjuvant therapies including RT and CT had a poor effect on PRSTSs, the primary treatment of PRSTSs should be radical resection with a wide margin.
  • [MeSH-major] Neoplasms, Second Primary / surgery. Sarcoma / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Breast Neoplasms / radiotherapy. Female. Histiocytoma, Benign Fibrous / etiology. Histiocytoma, Benign Fibrous / surgery. Humans. Japan. Male. Middle Aged. Neoplasm Recurrence, Local. Radiotherapy / adverse effects. Radiotherapy Dosage. Uterine Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] The Japanese Orthopaedic Association
  • (PMID = 15168177.001).
  • [ISSN] 0949-2658
  • [Journal-full-title] Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association
  • [ISO-abbreviation] J Orthop Sci
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Japan
  •  go-up   go-down


25. Pierlot A, Calteux N, Mataigne F, Colette JM: [Soft tissue sarcomas of the hand: report of a radiation-induced case]. Ann Chir Plast Esthet; 2001 Feb;46(1):45-54
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Soft tissue sarcomas of the hand: report of a radiation-induced case].
  • [Transliterated title] Les sarcomes des tissus mous de la main. A propos d'un cas de sarcome radio-induit.
  • Soft tissue sarcoma surgery is based on techniques that are in the process of ongoing development.
  • In this study, the case is reported of a female patient who was operated on at the age of 14 years for a primary synoviosarcoma of the dominant hand, which was treated by conservative surgery and 60 Gy adjuvant radiotherapy.
  • Amputation of the distal third of the forearm was performed.
  • The anatomopathological examination showed the presence of a myxoid malignant fibrous histiocytoma.
  • It was considered that this tumor had been radiation-induced.
  • All the distinct diagnostic criteria were met, i.e., a latency of over two years, different diagnosis and the appearance of the tumor within (or next to) the irradiated field.
  • Both the diagnostic methods (MRI, tumor biopsy, and CT scan of the chest to investigate possible tumor spread) and the surgical approach have been discussed.
  • Two main factors should be taken into account in treatment strategy: i) distant metastases of high-grade soft tissue sarcomas often appear early in the course of the disease, and are not affected by surgery at the primary site;.
  • Technical progress and a multidisciplinary approach have resulted in more sophisticated treatment (allowing a larger surgical resection area, and better residual function).
  • Surgical management remains the treatment of choice, as radiotherapy and chemotherapy have not demonstrated any positive effect on patient survival.
  • [MeSH-major] Forearm. Hand. Histiocytoma, Benign Fibrous / etiology. Neoplasms, Radiation-Induced / etiology. Neoplasms, Second Primary / etiology. Sarcoma, Synovial / radiotherapy. Soft Tissue Neoplasms / radiotherapy
  • [MeSH-minor] Adolescent. Amputation. Biopsy. Female. Humans. Magnetic Resonance Imaging. Neoplasm Staging. Survival Analysis. Tomography, X-Ray Computed

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11233734.001).
  • [ISSN] 0294-1260
  • [Journal-full-title] Annales de chirurgie plastique et esthétique
  • [ISO-abbreviation] Ann Chir Plast Esthet
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 79
  •  go-up   go-down


26. Schmitt T, Kasper B: New medical treatment options and strategies to assess clinical outcome in soft-tissue sarcoma. Expert Rev Anticancer Ther; 2009 Aug;9(8):1159-67
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New medical treatment options and strategies to assess clinical outcome in soft-tissue sarcoma.
  • Soft-tissue sarcomas (STSs) are a heterogeneous group of rare malignant tumors predominantly arising from the embryonic mesoderm.
  • The mainstay of curative therapy is the complete surgical resection of all tumor manifestations with negative histological margins.
  • First-line systemic therapy with ifosfamide and doxorubicin results in overall response rates of only 20% by conventional response evaluation criteria in solid tumors (RECIST).
  • Therefore, the role of the RECIST criteria has been questioned and the implementation of new imaging studies (e.g., FDG-PET) has shown promising results in assessing early tumor response to therapy.
  • Furthermore, a broader insight into the molecular pathways of sarcomagenesis has been gained in recent years, revealing intriguing targets for new therapeutic approaches (e.g., VEGF, VEGF receptor, IGF receptor, EGF receptor, mTOR and cyclin-dependent kinases).
  • In addition, a growing body of evidence is linking specific genetic aberrations with clinical outcome (e.g., SYT-SXX translocation in synovial sarcoma).
  • With further insight into the biology of STS and the combination of new treatment options with modern imaging techniques, we will most certainly be able to improve clinical outcome in patients with STS in the upcoming years.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Drug Delivery Systems. Sarcoma / therapy
  • [MeSH-minor] Humans. Neoplasm Metastasis. Positron-Emission Tomography / methods. Prognosis. Survival Rate. Treatment Outcome






Advertisement